Quest Diagnostics announced on March 20 the completion of its acquisition of select assets of Northern Light Laboratory, the outreach laboratory services business of Northern Light Health, a large integrated healthcare system in Maine.
The collaboration between the two parties is expected to enable physicians and patients throughout Maine to benefit from access to Quest’s test menu, network of patient access sites throughout the state, broad health plan coverage and lower out-of-pocket costs for many services. Quest’s laboratory in Marlborough, Massachusetts will provide the majority of advanced and routine clinical testing services for physicians and patients previously served by Northern Light Laboratory.
In addition, Quest now provides professional laboratory management services for nine of Northern Light Health’s hospital laboratories, along with its cancer center laboratory at Northern Light Cancer Care in Brewer, Maine. Financial details of the transaction were not disclosed.
Northern Light Laboratory (formerly Affiliated Laboratory, Inc.) began providing a full range of testing services to hospitals, clinics, physician’s offices and long-term care facilities in the Bangor, Maine area in 1983. Today, Northern Light Laboratory serves 250 physician practices throughout Maine and provides reference lab services for more than two dozen hospitals. It’s main testing laboratory operates 24/7.
Quest Diagnostics provides diagnostic testing information services in the United States and internationally. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States with approximately 50,000 employees.
According to data captured in the LevinPro HC database, this acquisition represents the 32nd Laboratories, MRI and Dialysis transaction of 2023 and the 16th in the diagnostics subsector. This also marks Quest Diagnostic’s second acquisition of the year. In February, the diagnostics company acquired select assets of the laboratory services business of NewYork-Presbyterian for an undisclosed price.
